Login to Your Account

Clinic Roundup

Monday, May 21, 2012
• NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said it enrolled the first patients in its Phase IIb study, named BAYnovation, to test lead compound NVC-422 in adenoviral conjunctivitis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription